Spanish Cell Therapy Network (TerCel) : 15 years of successful collaborative translational research
Sánchez-Guijo, Fermín (Universidad de Salamanca)
García-Olmo, Damián (Universidad Autónoma de Madrid)
Prósper, Felipe (Universidad de Navarra)
Martínez, Salvador (Instituto de Neurociencias UMH-CSIC)
Zapata, Agustín G (Universidad Complutense de Madrid)
Fernandez Aviles, Francesc (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Toledo-Aral, Juan José (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Torres, Miguel (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
Fariñas, Isabel (Universitat de València)
Badimon, Lina (Institut d'Investigació Biomèdica Sant Pau)
Labandeira-García, José Luis (Universidade de Santiago de Compostela)
García-Sancho, Javier (Universidad de Valladolid)
Moraleda, José M. (Universidad de Murcia)
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	In the current article we summarize the 15-year experience of the Spanish Cell Therapy Network (TerCel), a successful collaborative public initiative funded by the Spanish government for the support of nationwide translational research in this important area. Thirty-two research groups organized in three programs devoted to cardiovascular, neurodegenerative and immune-inflammatory diseases, respectively, currently form the network. Each program has three working packages focused on basic science, pre-clinical studies and clinical application. TerCel has contributed during this period to boost the translational research in cell therapy in Spain, setting up a network of Good Manufacturing Practice-certified cell manufacturing facilities- and increasing the number of translational research projects, publications, patents and clinical trials of the participating groups, especially those in collaboration. TerCel pays particular attention to the public-private collaboration, which, for instance, has led to the development of the first allogeneic cell therapy product approved by the European Medicines Agency, Darvadstrocel. The current collaborative work is focused on the development of multicenter phase 2 and 3 trials that could translate these therapies to clinical practice for the benefit of patients.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Cell therapy ; Regenerative medicine ; Research network ; Stem cells ; Translational medicine
Published in:	Cytotherapy, Vol. 22 Núm. 1 (january 2020) , p. 1-5, ISSN 1477-2566

DOI: 10.1016/j.jcyt.2019.11.001

5 p, 470.9 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles